MacroGenics cut to Neutral at Citi, Guggenheim upgrades

Nov. 23, 2022 9:31 AM ETMacroGenics, Inc. (MGNX)IMABBy: Dulan Lokuwithana, SA News Editor1 Comment

Wall street sign in New York with New York Stock Exchange background

naphtalina/iStock via Getty Images

MacroGenics (NASDAQ:MGNX) has garnered attention on Wall Street this week, with Citi downgrading the commercial-stage biotech on Wednesday to Neutral from Buy after an upgrade from Guggenheim a day earlier.

Citi analyst Yigal Nochomovitz removes

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.